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ABSTRACT 
Although allogeneic transplantation is a curative therapy for chronic myeloid leukemia (CML), treatment-related 
mortality is still a major cause of posttransplantation mortality, especially for patients older than 40 years. We inves- 
tigated, in a phase II trial, the role of a low-dose (550 cGy) high-dose rate (35 cGy/min) single-exposure total body 
irradiation (TBI) conditioning regimen for allogeneic peripheral blood stem cell (PBSC) transplantation in patients 
with CML. Between June 1997 and August 2000, 30 adult patients with CML underwent cytokine-mobilized allo- 
geneic PBSC transplantation from HLA-matched siblings following administration fcyclophosphamide (60mg/kg 
per day intravenously on days -2 and -1) and single-dose TBI (550 cGy delivered at 30 cGy/min on day 0). Cyclo- 
sporine A alone was administered for prophylaxis against graft-versus-host disease (GVHD). Median patient age 
was 47 years (range, 21-63 years), with 23 patients (77%) older than 40 years. The preparative r gimen was well tol- 
erated. Grade 4 toxicities and oral mucositis were not observed. Graft failure did not occur. Severe acute GVHD 
was observed in 5 patients (17%). The median follow-up was 23 months (range, 6-39 months). Cytogenetic or 
hematologic relapse was detected in 3 patients (10%), 2 of whom subsequently entered remission following a taper 
of immunosuppression. Nonrelapse mortality occurred in 5 patients (17%), and the Kaplan-Meier stimate of sur- 
vival at 2 years was 83% (95% confidence interval, 70%-97%). In summary, this low-dose TBI-based preparative 
regimen resulted in uniform donor engraftment, with markedly reduced organ toxicity and nonrelapse mortality, in 
this relatively older cohort of patients with CML. 
KEY WORDS 
Chronic myeloid leukemia ~ Single-dose total body irradiation ~ Transplant-related toxicity 
INTRODUCTION 
Chronic myeloid leukemia (CML) is a clonal myelopro- 
liferative disorder characterized by a balanced reciprocal 
translocation between the long arms of chromosomes 9 and 
22. The incidence of CML increases with age, and the 
median age at diagnosis is 67 years [1-3]. Allogeneic 
hematopoietic stem celltransplantation (HSCT) is the only 
known curative treatment modality for patients with CML. 
However, this procedure is often restricted to younger 
patients due to increased transplantation-related mortality 
with older age. Allogeneic HSCT is effective in eradicating 
the CML cells through the cytoreductive effect of the con- 
ditioning regimen and the graft-versus-leukemia (GVL) 
effect. The GVL effect was suspected when low relapse rates 
were observed after unmodified bone marrow transplanta- 
tion in contrast to T-cell-depleted or syngeneic transplanta- 
tion [4] and was confirmed by the achievement of prolonged 
remissions after infusion of donor leukocytes in the majority 
of CML patients with postallograft relapse [5,6]. The 
cytoreductive potential of the conditioning regimen in 
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Table I. Patiem Characteristics* 
Median age, y (range) 47 (21-63) 
Patient age 
<40 y 7 (23%) 
40-49 y I I (37%) 
50-59 y 8 (27%) 
_>60 y 4 (I 3%) 
Patient sex 
Male 16 (54%) 
Female 14 (46%) 
Time from diagnosis to transplantation 
< 12 mo 19 (63%) 
>12 mo I I (37%) 
Interferon trial prior to transplantation 18 (60%) 
Matching of donor and recipient 
Sex matched 15 (50%) 
Female/male 7 (23%) 
*N = 30. Data are n (%) of patients unless otherwise indicated. 
CML is well demonstrated by achievement of long-term 
disease-free survival after syngeneic transplantation [7] and 
improved disease-free survival with intensification of total 
body irradiation (TBI) doses in preparation for allografting 
[8]. However, transplantation-related mortality is a limiting 
factor for dose intensification of the conditioning regimen, 
as demonstrated bya lack of survival benefit in patients ran- 
domized to receive higher doses of TBI [8]. 
In a search for the ideal conditioning regimen that 
would offer the benefits of the potent GVL effect in CML 
with reduced transplantation-related toxicity, we investi- 
gated the role of low-dose TBI conditioning for HLA- 
matched sibling allogeneic peripheral blood stem cell 
(PBSC) transplantation. This preparative regimen was 
inspired by experience at the University of Toronto [9] and 
was developed based on observations in dog models, in 
which both single-dose and fractionated-TBI schemas were 
shown to have comparable myeloablative potentials [10]. 
Greater immunosuppressive effects were observed, however, 
after single-dose TBI compared with fractionated TBI when 
both schemas were given at equal total doses and dose rates 
[11]. The use of a high versus a standard ose rate in the 
administration of low-dose single-exposure TBI resulted in 
consistent engraftment of donor cells, with minimal non- 
hematologic toxicity and minimal graft-versus-host disease 
(GVHD) [12]. We therefore hypothesized that, in humans, 
a low-dose TBI regimen would result in sustained allogeneic 
PBSC engraftment similar to bone marrow engraftment [9], 
with reduced toxicity, if given as a single dose and at a high 
dose rate. The objectives of this trial were the evaluation of 
early toxicities and nonrelapse mortality, engraftment rate, 
relapse risk, and survival of CML patients treated with this 
low-dose TBI-based conditioning regimen. 
MATERIALS AND METHODS 
Pat ients  
Between June 1997 and August 2000, 30 consecutive 
adult patients with Philadelphia chromosome-positive CML 
were condit ioned with the low-dose TBI  regimen as 
described below in preparation for allogeneic PBSC trans- 
plantation from an HLA-matched sibling. Most patients 
were diagnosed at other institutions and were referred to 
Washington University for transplantation. The diagnosis 
was confirmed by an instinttional review of outside patho- 
logic material and cytogenetic analysis. All patients enrolled 
in the low-dose TBI protocol are included in this analysis. 
The Institutional Review Board of the Washington Univer- 
sity School of Medicine approved the study, and all patients 
and donors gave written informed consent. 
Patient characteristics are summarized in ~Ihble 1, and 
were as follows: median age, 47 years (range, 21-63 years), 
23 patients (77%) were older than 40 years; median time from 
diagnosis to transplantation, 9 months (range, 3-69 months), 
and 19 patients (63%) received transplants within a year 
after the diagnosis of CML. Pretransplantation interferon 
was administered to 18 patients (60%) and was discontinued 
within 3 months prior to transplantation i  15 of these 
patients. Seven male transplant recipients (23%) received 
PBSCs from a female donor. Except for 2 patients who pre- 
sented at diagnosis with a single extramedullary (bone) 
leukemic site, and therefore would be best classified as 
patients with blast-phase CML, all patients had morpho- 
logic and cytogenetic features of chronic-phase CML. 
HLA Typing 
HLA matching was performed using serologic methods 
for HLA A and B antigens. Class II HLA antigens were 
typed with high-resolution sequence-specific oligonucleotide 
probes for HLA-DRB1 alleles. 
Conditioning Regimen 
Conditioning included administration of cyclophos- 
phamide (60 mg/kg per day intravenously [IV] on days 2 
and 1 pretransplantation), methylprednisolone (1000 mg/d 
IV on days 2 and 1 pretransplantation), and low-dose 
(550 cGy) TBI delivered as a single dose at a high dose rate 
(30 cGy/min, -+15%) on day 0. Because of the concern that 
graft failure might occur, methylprednisolone was included 
in the conditioning for recipient in vivo immune suppres- 
sion. The irradiation was delivered in parallel and opposed 
lateral fields with a 6-MV photon linear accelerator (Clinac 
600 CD; Varian Medical Systems, Alpharetta, GA). Patients 
were treated in a sitting position with a 300-cm source-to- 
midline distance. The point-of-dose prescription was a sin- 
gle point, midline in the body, at the level of the umbilicus. 
A large lucite plate was placed near the patient o enhance 
the skin dose and a tissue compensator was used to keep the 
midline dose to the head and neck to within 110% of the 
prescription dose. The arms provided partial ung shielding. 
Both ion chamber and diodes placed on different parts of 
the body were used to ensure that the measured and calcu- 
lated doses were within acceptable imits. The mean actual 
dose rate was 31.7 cGy/min (range, 26.4-36.0 cGy/min). 
Mobi l i za t ion  and  Co l lec t ion  o f  Donor  S tem Ce l l s  
Donor cells were mobilized with granulocyte colony- 
stimulating factor (G-CSF) at 10 gg/kg subcutaneously (SC) 
daily for 5 days (n = 23), granulocyte-macrophage (GM)- 
CSF at 5 gg/kg SC daily for 5 days (n = 1), or a combination 
of G-CSF and GM-CSF (n = 6). PBSCs were collected 
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through a single large-volume apheresis (20 L) on the fifth 
day of growth factor administration aspreviously described 
[13]. Except for red blood cell depletion for ABO incompat- 
ibility (n = 4), the pheresis product was unmanipulated and 
administered immediately tothe recipient. 
GVHD Prophylaxis and Supportive Care 
Because of the concern that graft failure and relapse of 
CML might occur, oral cyclosporine A (CSA), 12.5 mg/kg 
per day, was initiated on day -2 as a single agent for GVHD 
prophylaxis. Patients unable to take CSA orally received the 
drug IV at a dosage of 3 mg/kg per day (as a 4-hour infusion 
in 2 divided doses) until they were able to tolerate the oral 
formulation. Whole-blood trough CSA levels were meas- 
ured at least twice weekly, with dosage adjustments made to 
achieve the desired drug level of 200 to 400 ng/mL. From 
day 100 to 6 months posttransplantation, CSA was tapered 
off at a rate of approximately 5% per week in those patients 
without active GVHD. 
G-CSF (Neupogen; Amgen, Thousand Oaks, CA), 
10 btg/kg per day SC, was started on posttransplantation day 
1 for the first 20 patients and subsequently changed to day 5 
due to adverse side effects, as previously described [14]. 
G-CSF was discontinued when the absolute neutrophil 
count (ANC) was greater than 1500/btL for 2 consecutive 
days following the nadir ANC. 
All patients received either irradiated blood products 
from donors who were seronegative for cytomegalovirus 
(CMV) or leukocyte-depleted irradiated blood products 
from donors who were seropositive for CMV. Prophylactic 
granulocyte components mobilized with G-CSF were col- 
lected from the stem cell donor if the donor was ABO 
compatible with the recipient and met standard criteria to 
donate grannlocyte components (n = 19) and were trans- 
fused on days 5 and 7 posttransplantation, as previously 
described [15]. Trimethoprim-sulfamethoxazole was initi- 
ated 1 week after neutrophil engraftment at a dosage of 
1 double-strength tablet twice a day twice weekly for pro- 
phylaxis against P~'zeu~ocystis carinii. Prophylactic acyclovir 
was administered orally at a dosage of 400 mg 3 times per 
day starting on posttransplantation day 1. Prophylactic 
antibacterial or antifungal agents were not used. Episodes 
of febrile neutropenia were treated with broad-spectrum 
antibiotics with the subsequent addition of amphotericin-B 
for suspected fungal infections. Upon engraftment and 
until day 150 posttransplantation, surveillance testing of 
blood for CMV was performed every 2 weeks using rou- 
tine viral culture and shell vial culture of bully-coat speci- 
mens. CMV viremia was treated with ganciclovir 5 mg/kg 
IV daily for 21 days. 
Engraftment and Chimerism 
Neutrophil engraftment was defined as the first of 
3 consecutive days in which the ANC exceeded 500/btL. 
Platelet engraftment was defined as the first 7 consecutive 
days in which the platelet count exceeded 50,O00/btL with- 
out platelet ransfusion. The presence of donor cells was 
determined on days 30, 100, 180, and 365 posttransplanta- 
tion by the detection of an informative variable number of 
tandem-repeat (VNTR) polymorphisms, as previously 
described [16,17]. Sensitivity of current VNTR analysis is 
1% to 5%. Engraftment was defined as complete if 95% to 
100% of marrow cells were of donor origin or defined as 
mixed if more than 5% of marrow cells were of host origin. 
Graft failure was defined as the failure to achieve an ANC 
greater than 500/btL for at least 3 consecutive days, a 
decrease in the ANC to less than 500/btL for at least 3 con- 
secutive days after initial engraftment, or documentation f 
the loss of donor ceils. 
Regimen-Related Toxicity 
Early regimen-related toxicity was graded using the 
National Cancer Institute criteria for bone marrow trans- 
plantation studies, in which grade 0 indicated no toxicity, 
grade 4 indicated life-threatening toxicity, and grades 1 to 3 
indicated increasing levels of toxicity. 
Relapse 
To monitor disease status, bone marrow aspirates and 
biopsies were obtained on days 30, 100, 180, and 365 post- 
transplantation, and yearly thereafter for morphologic 
analysis, routine cytogenetic analysis, and analysis for the 
presence of the bcr-abl transcript using qualitative poly- 
merase chain reaction (PCR). Relapse was defined as either 
hematologic evidence of recurrent CML or the detection of 
a Philadelphia chromosome by routine cytogenetic analysis 
on at least 2 consecutive occasions in patients with a normal 
blood-cell differential count and normal bone marrow mor- 
phology with no active therapeutic intervention (such as 
donor lymphoid infusion or interferon) instituted between 
the 2 analyses. Detection of the bcr-abl transcript by qualita- 
tive reverse transcriptase (RT)-PCR was not considered a 
criterion for relapse [18,19]. 
Statistical Analysis 
Quantitative parameters are provided as median or 
mean with standard eviation. Cumulative actuarial proba- 
bilities of survival and leukemia-flee survival were calculated 
as of February 2001, using the Kaplan-Meier method [20]. 
RESULTS 
Engraftment and Chimerism 
The median dose of CD34 + cells infused was 6.2 x 106/kg 
(range, 2.8-16.2 x 106/kg). The median times to neutrophil 
and platelet engraftment were 11 days (range, 6-15 days) and 
14 days (range, 10-78 days), respectively. Graft failure was 
not observed. 
Complete donor chimerism was observed in 93 %, 92%, 
86%, and 95% of evaluable patients on days 30, 100, 180, 
and 365 posttransplantation, respectively (Table 2). Mixed 
chimerism was observed in 6 patients (20%) in at least 1 of 
the time points assessed posttransplantation. Five of those 
patients converted back to full donor chimerism sponta- 
neously (n = 2) or with taper of immunosuppression (n = 3), 
whereas 1 patient died with persistent mixed chimerism. 
Regimen-Related Toxicity 
In this cohort of relatively older patients with CML, 
transplantation was extremely well tolerated (Table 3). 
Grade 4 toxicities, oral mucositis, and interstitial pneumoni- 
tis did not occur. Grade 3 toxicity was observed in only 
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Tab le  2. Results of Cbimerism Analyses* 
Patients' Donor Cell Percentage 
T ime Posttransplantation 95%- 100% 90%-94% 50%-89% 0% Nonevaluable Patients t 
30 d 26 I I 0 2 
100 d 23 0 25 0 5 
180 d 18 0 3w 0 9 
l y 20 0 I 0 9 
*Data are number of patients. 
tNonevaluable due to death, not done, or short follow-up. 
SPatient with cytogenetic relapse (n = 1). 
~Patient with hematologic and cytogenetic relapse (n - 1). 
2 patients (7%). No patient required hemodialysis. One 
patient developed hyperbil irubinemia (grade 2), best 
described as liver dysfimction on unknown etiology, on day 
7 posttransplantation that resolved after administration of 
high-dose corticosteroids, as previously described [21]. 
Neutropenic fever was observed in 22 patients and bac- 
teremia was detected in 12 of these patients (10 Staphylococcus 
coagulase negative, 2 Gram-negative). The median duration 
of hospitalization was short, 19 days (range, 15-30 days) for 
the transplantation hospitalization, and 23 days (range, 15- 
60 days) through day 100 posttransplantation. 
Between days 100 and 365 posttransplantation, 6 patients 
developed nonneutropenic bacteremia attributed to central 
venous catheter access (n = 4) or pneumonia (n = 2). CMV 
viremia was detected in surveillance cultures of blood in 
6 patients (20%), and all patients were successfully treated 
with a 2 l-day course of ganciclovir resulting in clearance of 
the viremia. BK virus-related hemorrhagic ystitis was 
observed in 3 patients. Invasive fungal infection was 
detected in 5 patients, 2 of whom died from their infections. 
Two patients were diagnosed with nephrotic syndrome of 
unclear etiology, 1 patient at 14 months and 1 at 25 months 
posttransplantation. 
Graft-Versus-Host Disease 
The incidence of severe acute GVHD (International 
Bone Marrow Transplant Registry [IBMTR] severity indices 
C-D [22] or Glucksberg [23] grades III-IV) was 17% 
(occurring in 5 patients). Although the majority of patients 
developed acute GVHD (n = 27, 90%), the presentation was 
most commonly single organ, steroid sensitive, and limited 
to the skin (n = 19, 63%). Table 4 summarizes the stages of 
various organs involved in acute GVHD. 
The cumulative incidence stimate of chronic GVHD was 
92% for the 26 patients who survived for at least 100 days. In 
all patients, chronic GVHD was extensive (not limited to 
isolated liver function test abnormalities or localized skin 
involvement) [23]. Among the 14 patients alive with follow- 
up through 2 years who developed chronic GVHD, 4 (29%) 
successfully discontinued immunosuppressive th rapy. 
Relapse and Survival 
The median duration of follow-up was 23 months 
(range, 6-39 months). Cytogenetic (n = 3) or hematologic 
relapse (n = 2) was detected in 3 patients on days 100 and 
180 and 15 months posttransplantation. Sustained complete 
hematologic, cytogenetic, and molecular emission was 
observed after transient discontinuation f immunosuppres- 
sion in 2 of these patients, whereas 1 patient died from sep- 
sis with persistent hematologic and cytogenetic evidence of 
chronic-phase CML. 
In 13 patients, the presence of the bcr-abl transcript was 
detected transiently by qualitative RT-PCR on at least 1 of 
the time points assessed posttransplantation (days 30, i00, 
180, and 365). Ten patients tested PCR-positive for bcr-abl 
on day 180 (n = 5) or 365 (n = 5) posttransplantation. Of the 
5 patients that tested PCR-positive on day 180, 1 patient 
had cytogenetic relapse and 4 patients had bcr-abl unde- 
tectable by PCR on and beyond day 365 posttransplanta- 
tion. Of the patients who tested PCR-positive for bcr-abl on 
day 365 posttransplantation, conversion to PCR negativity 
was observed in 2 of those 5 patients at 18 (n = 2), 24 (n = 2), 
and 42 months (n = 1) posttransplantation, whereas 
3 patients had persistent PCR positivity at 18 (n = 2) and 
42 months (n = 1) posttransplantation. Cytogenetic relapse 
occurred in 2 of those 3 patients. 
The Kaplan-Meier estimate of survival at 2 years was 
83% (95% confidence interval, 70%-97%) (Figure). Five 
patients died, on days 57, 59, 62, 92, and 213 posttransplan- 
tation. The cause of death in all 5 patients was infection 
associated with severe GVHD. The day 100 mortality rate 
was 10% (3/30 patients). 
Performance Scores 
Nine of 14 patients with 2 or more years of follow-up 
were able to carry on normal activities with no signs or 
minor signs or symptoms of chronic GVHD and/or side 
effects from its treatment (Karnofsky score of 80%-100%). 
Table 3. Trearment-Rdated Toxicity 
National Cancer Institute Toxicity Grade 
Tissue~organ None I 2 3 4 
Oral mucosa 30 0 0 0 0 
Hepatic 29 0 I 0 0 
Bladder 27 3 0 0 0 
Renal 20 0 8 2 0 
Cardiac 30 0 0 0 0 
Central nervous system 30 0 0 0 0 
Pulmonary 30 0 0 0 0 
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Table 4. dc.,te Graft- Verszt, s-t [ost Disease* 
Organ 
Stage Skin Gut  Liver 
I 6 0 3 
II 17 2 0 
III 4 0 I 
IV 0 3 2 
Glucksberg Grade 
I-II III IV 
22/30 (73) 2/30 (7) 3/30 (10) 
*Data are n or n (%). 
DISCUSSION 
Despite improvements in supportive care, conventional 
allogeneic HSCT is associated with significant toxicity and 
early mortality, especially for patients older than 40 years 
[24]. Because CML is a disease that occurs in the fifth 
decade of life or later in most patients and GVL is a major 
contributor to the curative potential of allogeneic HSCT 
for this disease, investigating the role of less intense condi- 
tioning for CML is justifiable. This study described a low- 
dose TBI-based preparative r gimen for alloengraftment i  
patients with CML. This conditioning regimen using sin- 
gle-dose TBI was inspired by the experience of the Univer- 
sity of Toronto [9] and was developed based on observations 
from dog models [10] and on modifications of the conven- 
tional cyelophosphamide/TBI regimen [8]. The TBI was 
given as a single low dose (550 cGy) delivered at a high dose 
rate (30 cGy/min). The source of stem cells was cytokine- 
mobilized PBSCs. 
Using this low-dose single-exposure TBI-based regi- 
men, complete ngraftment ofHLA-matched related onor 
cells was observed in the majority of evaluable patients 
(86%-95%) at the time points that chimerism was assessed 
posttransplantation. Engraftment of donor cells was durable 
given that complete donor engraftment extended through 
2 years posttransplantation. Graft failure did not occur. 
Importantly, the conditioning was extremely well toler- 
ated in this cohort of relatively older patients (77% older than 
40 years). The duration of cytopenia was brief (11-14 days), 
the incidence of neutropenic complications was low, and the 
hospitalization period was short (19 days). No patients 
developed grade 4 toxicity, idiopathic pneumonitis, or 
significant hepatic veno-occlusive disease. Additionally, the 
use of this conditioning eliminated oral mucositis as a com- 
plication of transplantation. I  this study, the nonrelapse 
mortality rate was 17%, which is similar to, if not lower 
than, the reported rates associated with standard condition- 
ing therapies (20%-41%) [25,26]. 
A major concern in the initial design of this trial was 
ensuring that any potential gain by reduction of nonrelapse 
mortality was not offset by an increased risk of leukemic 
relapse. In this single-institution experience describing a
small number of patients with a relatively short follow-up 
period (median 23 months, with a minimum follow-up of 
6 months), the relapse rate was low (3/30 patients). Two of 
the 3 relapsing patients achieved sustained complete hemato- 
logic and cytogenetic remission after transient discontinua- 
tion of immunosuppression. Although patients are still at risk 
for relapse with longer follow-up, these results are encourag- 
ing taking into account that most studies report relapse rates 
within 3 to 5 years of 20% and that the majority of CML 
relapses occur in the first 2 years posttransplantation [8,25]. 
In murine models, the incidence and severity of acute 
GVHD increases with higher TBI doses [27]. It has been 
hypothesized that increased gut injury from higher doses of 
TBI leads to greater elease of systemic inflammatory 
cytokines resulting in the development of acute GVHD 
[27,28]. Observations from clinical studies upported this 
hypothesis, showing that increased total doses of TBI 
(1200 cGy versus >1200 cGy)were independent risk factors 
for development of grades II to IV acute GVHD [29]. 
Whether the incidence and severity of GVHD varies across 
lower total doses of TBI (550 cGy versus 1200 cGy) is 
unclear in the absence of controlled trials. Nevertheless, the 
outcomes observed in our study argue in favor of such a 
hypothesis. Indeed, the incidence of severe acute GVHD 
(IBMTR severity indices, C-D) with this low-dose TBI reg- 
imen was relatively low (17%) in a cohort of older patients 
with CML given CSA alone for GVHD prophylaxis. 
Although acute GVHD was very common immediately after 
engraftment, it manifested mainly with mild steroid-sensitive 
skin involvement. Deeg et al. reported a 40% incidence of 
severe acute GVHD observed in patients who received CSA 
alone following HLA-matched sibling marrow transplanta- 
tion using fractionated TBI-based regimens [30]. Another 
study reported a 28% incidence of severe acute GVt-ID in 
patients with leukemia undergoing HLA-matched sibling 
marrow transplantation f llowing administration f cyclophos- 
phamide and 1200 cGy of fractionated TBI (at 6.5 cGy/min) 
and randomized to receive CSA alone [31]. 
The long-term incidence of chronic GVHD in patients 
undergoing a low-dose TBI conditioning regimen remains 
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to be determined with further follow-up. However, the fact 
that 92% of patients who survived for at least 100 days 
developed chronic GVHD suggests that the long-term inci- 
dence of chronic GVt-ID might not be different from that 
seen in patients undergoing standard conditioning for allo- 
geneic PBSC transplantation [32,33] and that this high inci- 
dence probably relates to the source of stem cells rather 
than the conditioning regimen. Whereas chronic GVHD 
may contribute to improved disease-free survival rates in 
patients with CML [34], such patients are at greater isk of 
morbidity and mortality from infections complications. 
Thus, the effect of chronic GVHD on late nonrelapse mor- 
tality needs to be monitored with longer follow-up. How- 
ever, it was encouraging to observe that no patient in this 
study died from chronic GVI-[D or regimen-related toxicity 
beyond 7 months posttransplantation. 
In this study, the Kaplan-Meier estimate of 2-year sur- 
vival was 83%. This preliminary outcome is encouraging 
when compared with those reported for younger CML 
patients conditioned with conventional TBI -based regi- 
mens. For patients with CML in chronic phase undergoing 
HLA-matched sibling marrow transplantation following 
delivery of fractioned TBI  (1200 cGy at 6-7 cGy/min) and 
administration of cyclophosphamide, the reported 4-year 
disease-free and overall survival rates were 58% and 60%, 
respectively [8]. If the excellent survival outcome and the 
low organ-toxicity profile observed in this trial are con- 
firmed in a larger-scale study, then, pending information on 
the impact of STI-571 on the natural history of CML, the 
use of up-front allogeneic HSCT might be the preferred 
treatment modality for the majority of patients with newly 
diagnosed CML who have an HLA-matched related donor. 
Recently, several groups evaluated less intense nonmye- 
loablative conditioning regimens for donor transplantation 
as novel strategies to reduce treatment-related toxicity. 
Giralt et al. [35] observed that purine analog-based regi- 
mens were well tolerated. McSweeney et al. observed similar 
outcomes using a regimen that employed 200-cGy single- 
dose TB I  given with cyclosporine and mycophenolate 
mofetil [36]. However, these strategies were initially associ- 
ated with a low likelihood of early complete donor chimerism, 
an approximate 20% risk of graft rejection, and a high risk 
of leukemic relapse in patients with CML, which prompted 
subsequent intensification of the conditioning regimen or 
administration of donor lymphoid infusions. GVt-ID was a 
frequent complicat ion in those patients who achieved 
complete donor chimerism and a common cause of trans- 
plantation-related mortality. The potential to generate 
mixed-chimerism states with low toxicity is the primary 
impetus for continued investigation of these novel regimens. 
In this study, the regimen used was low-dose TBI-based 
myeloablative conditioning, which was associated with low 
organ toxicity and nonrelapse mortality and a re1T favorable 
2-year survival rate without adversely affecting the relapse 
risk to date. The regimen described herein may therefore 
represent an alternative to standard conditioning regimens 
and their associated toxicities and to the nonmyeloablative 
conditioning regimens that are associated with a high risk of 
graft rejection and relapse. 
In summary, in this study, we have shown that low-dose 
(550 cGy) single-exposure TBI  given at a high dose rate 
(30 cGy/miu) along with cyclophosphamit e was associated 
with low- acute organ toxici W and nonrclapsc mortality rates 
in a relatively older cohort of patients and that reliable 
donor PBSC engraftment was achieved. Despite a decrease 
in the intensity of TBI, no increases its early relapse rates 
were observed. 
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